Kanada - İngilizce - Health Canada

takeda canada inc - lanthanum (lanthanum carbonate hydrate) - tablet (chewable) - 1000mg - lanthanum (lanthanum carbonate hydrate) 1000mg - phosphate-removing agents

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - lanthanum carbonate hydrate, quantity: 1908 mg - tablet, chewable - excipient ingredients: dextrates; magnesium stearate; silicon dioxide - treatment of hyperphosphataemia in adults with chronic renal failure on haemodialysis or continuous ambulatory peritoneal dialysis (capd).

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - lanthanum carbonate hydrate, quantity: 1431 mg - tablet, chewable - excipient ingredients: dextrates; magnesium stearate; silicon dioxide - treatment of hyperphosphataemia in adults with chronic renal failure on haemodialysis or continuous ambulatory peritoneal dialysis (capd).

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - lanthanum carbonate hydrate, quantity: 954 mg - tablet, chewable - excipient ingredients: dextrates; silicon dioxide; magnesium stearate - treatment of hyperphosphataemia in adults with chronic renal failure on haemodialysis or continuous ambulatory peritoneal dialysis (capd).

İsrail - İngilizce - Ministry of Health

takeda israel ltd - lanthanum as carbonate hydrate - chewable tablets - lanthanum as carbonate hydrate 500 mg - lanthanum carbonate - lanthanum carbonate - fosrenol is indicated as a phosphate binding agent for use in the control of hyperphosphatemia in crf patients on haemodyalisis or continuous ambulatory peritoneal dialysis (capd).fosrenol is also indicated in adult patients with chronic kidney disease not on dialysis with serum phosphate levels > or = 1.78 mmol/l in whom a low phosphate diet alone is insufficient to control serum phosphate levels.

İsrail - İngilizce - Ministry of Health

takeda israel ltd - lanthanum as carbonate hydrate - chewable tablets - lanthanum as carbonate hydrate 750 mg - lanthanum carbonate - lanthanum carbonate - fosrenol is indicated as a phosphate binding agent for use in the control of hyperphosphatemia in crf patients on haemodyalisis or continuous ambulatory peritoneal dialysis (capd).fosrenol is also indicated in adult patients with chronic kidney disease not on dialysis with serum phosphate levels > or = 1.78 mmol/l in whom a low phosphate diet alone is insufficient to control serum phosphate levels.

İsrail - İngilizce - Ministry of Health

takeda israel ltd - lanthanum as carbonate hydrate - chewable tablets - lanthanum as carbonate hydrate 1000 mg - lanthanum carbonate - lanthanum carbonate - fosrenol is indicated as a phosphate binding agent for use in the control of hyperphosphatemia in crf patients on haemodyalisis or continuous ambulatory peritoneal dialysis (capd).fosrenol is also indicated in adult patients with chronic kidney disease not on dialysis with serum phosphate levels > or = 1.78 mmol/l in whom a low phosphate diet alone is insufficient to control serum phosphate levels.

İsrail - İngilizce - Ministry of Health

takeda israel ltd - lanthanum as carbonate hydrate - powder - lanthanum as carbonate hydrate 1000 mg - lanthanum carbonate - fosrenol is indicated as a phosphate binding agent for use in the control of hyperphosphatemia in crf patients on haemodyalisis or continuous ambulatory peritoneal dialysis (capd). fosrenol is also indicated in adult patients with chronic kidney disease not on dialysis with serum phosphate levels ≥ 1.78 mmol/l in whom a low phosphate diet alone is insufficient to control serum phosphate levels.

İsrail - İngilizce - Ministry of Health

takeda israel ltd - lanthanum as carbonate hydrate - powder - lanthanum as carbonate hydrate 750 mg - lanthanum carbonate - fosrenol is indicated as a phosphate binding agent for use in the control of hyperphosphatemia in crf patients on haemodyalisis or continuous ambulatory peritoneal dialysis (capd). fosrenol is also indicated in adult patients with chronic kidney disease not on dialysis with serum phosphate levels ≥ 1.78 mmol/l in whom a low phosphate diet alone is insufficient to control serum phosphate levels.

Kanada - İngilizce - Health Canada

takeda canada inc - lanthanum (lanthanum carbonate hydrate) - tablet (chewable) - 250mg - lanthanum (lanthanum carbonate hydrate) 250mg - phosphate-removing agents